Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis

SF3B1 gene mutations are the most frequent mutations found in myelodysplastic syndromes (MDS), and the prognostic implication of these mutations remains controversial. We conducted a meta-analysis of studies assessing the prognostic impact and clinical feature of SF3B1 mutations in MDS patients. The overall hazard ratio for overall survival (OS) was 0.90 (95% confidence interval 0.60-1.35, P  = 0.61) in MDS patients with SF3B1 mutations compared to those without. Lower leukemia-free survival was associated with SF3B1 mutations.

Source: Critical Reviews in Oncology Hematology - August 3, 2018 Category: Cancer & Oncology Authors: Yaqiong Tang, Miao Miao, Shiyu Han, Jiaqian Qi, Hong Wang, Changgeng Ruan, Depei Wu, Yue Han Source Type: research